Question · asked by 1 review
Summary of findings: levofloxacin for inhalation solution vs tobramycin: Adverse events: number of treatment‐related adverse events
- Population
- adults and children aged over 12 with CF and P aeruginosa
- Intervention
- Summary of findings: levofloxacin for inhalation solution
- Comparison
- tobramycin
- Outcome
- Adverse events: number of treatment‐related adverse events
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: levofloxacin for inhalation solution vs tobramycin Adverse events: number of treatment‐related adverse events · adults and children aged over 12 with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 282 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.